|
Synonyms: JS-002 | JS002 | Junshida®
ongericimab is an approved drug
Compound class:
Antibody
Comment: Ongericimab (JS002) is a subcutaneous humanized anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibody [1]. It blocks binding between circulating PCSK9 and the LDL receptor on hepatocytes. This reduces LDL receptor degradation, thus increasing the number of LDL receptors on cells, and effectively increasing hepatic removal LDL cholesterol (LDL-C) from the circulation. Ongericimab was developed for patients at high risk for cardiovascular disease, as an add-on treatment when standard lipid-lowering therapy fails to achieve LDL-C target level.
|
| References |
|
1. Jiang J, Xu L, Chai L, Guan X, Zhang L, Liu H, Yan Y, Li L, Zhao Y, Bai X et al.. (2024)
Clinical pharmacokinetics and pharmacodynamics of ongericimab: A potential long-acting PCSK9 monoclonal antibody in healthy subjects and patients with hypercholesterolemia: Randomized, double-blind, placebo-controlled phase Ia and Ib/II studies. Clin Transl Sci, 17 (11): e70061. [PMID:39498965] |
|
2. Lin J, Ji Y, Wang G, Ma X, Yao Z, Han X, Chen J, Chen J, Huang W, Xu G et al.. (2025)
Efficacy and safety of ongericimab in Chinese patients with heterozygous familial hypercholesterolemia: A randomized, double-blind, placebo-controlled phase 3 trial. Atherosclerosis, 403: 119120 [Epub ahead of print]. [PMID:39999660] |
|
3. Wang X, Qiu M, Cheng Z, Ji X, Chen J, Zhu H, Tang Y, Huang Z, Su G, Wang G et al.. (2024)
Efficacy and Safety of Ongericimab in Chinese Patients With Primary Hypercholesterolemia and Mixed Dyslipidemia. J Am Heart Assoc, 13 (11): e033669. [PMID:38818934] |
